What happens when you stop taking Mounjaro?
Medications such as Ozempic and Mounjaro are delivering impressive results for weight loss and metabolic health.
But new research highlights an important reality:
The results don’t always last once the medication stops.
The challenge: maintaining results post-medication
Recent evidence shows that:
A significant proportion of weight lost is regained after stopping GLP-1 medications
Appetite increases as the medication effect is removed
Key health markers can begin to trend back toward baseline
This isn’t a failure of willpower, it’s a physiological response.
These medications work by suppressing appetite and regulating intake.
When they are removed, those signals return.
Why this matters for individuals and businesses
GLP-1 use is growing rapidly, including within the workplace.
But many people are:
Losing weight without a clear nutrition strategy
Struggling with low energy, poor intake, or side effects
Unprepared for what happens when they come off the medication
This creates a gap between short-term results and long-term sustainability.
Our approach: supporting results beyond the medication
At True Food, our GLP-1 nutrition support services are designed to bridge that gap.
We focus on:
Protecting muscle mass and metabolic health during weight loss
Practical strategies for eating well with reduced appetite
Building sustainable habits that support long-term success
Preparing individuals for a safe and effective transition off medication
The bottom line
GLP-1 medications are powerful tools, but they are not a complete solution on their own.
Long-term success depends on what happens alongside them.
That’s where the right nutrition support makes the difference.
References
Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., McGowan, B.M., Rosenstock, J., Tran, M.T.D., Wadden, T.A. and Wharton, S. (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism, 24(8), pp. 1553–1564.
Tzang, C.C. et al. (2025) Metabolic rebound after GLP-1 receptor agonist discontinuation: A systematic review and meta-analysis, Obesity Reviews.